Abstract 2540: Immune modulation by the TLR8 agonist VTX-2337; a comparison of the pharmacodynamic response in cancer patients and healthy volunteers

Abstract

Abstract Immunotherapy has proven to be a successful treatment approach for some cancer patients. One promising paradigm in immunotherapy is targeting pathogen-associated molecule pattern receptors (PAMPS) such as the toll-like receptors (TLRs) to activate the innate immune system and enhance the development of tumor-directed adaptive immune responses. However, an ongoing concern in the application of immunotherapeutics is the potential for the immune response in cancer patients to be less robust than in healthy individuals, due to the underlying advanced neoplastic disease or due to previous regimens of cytotoxic drugs. To address this concern in relation to the response to TLR8 stimulation, we compared the pharmacokinetic and pharmacodynamic (PK/PD) relationship defined in a phase 1 clinical trial of the selective small molecule TLR8 agonist VTX-2337 in oncology patients to the response in healthy volunteers. A phase 1 dose-escalation clinical trial (A101) in subjects with advanced solid tumors (n=33) demonstrated that plasma levels of multiple biomarkers of immune activation, including G-CSF, MCP-1, MIP1-β and TNFα, increased in a dose-dependent manner and correlated with increasing plasma levels of VTX-2337. The PK/PD relationship defined in the initial clinical trial was closely aligned with predictions from both in vitro assays and preclinical studies conducted in cynomolgus monkeys. A subsequent phase 1 trial (A105) was conducted as a single-center, open-label, two-period, randomized, crossover, phase 1 study in normal volunteers (n=10). The objective of this study was to compare the PK/PD profiles and local tolerance of two formulations of VTX-2337. In this study, the two preparations of VTX-2337 demonstrated comparable PK profiles and PD responses. At comparable dose levels, the PK profile and overall exposure (AUC) to VTX-2337 was similar for oncology patients and healthy volunteers. VTX-2337 induced the same repertoire of circulating cytokines and chemokines, indicative of TLR8 activation, in both populations. The magnitude of the mediator response in oncology patients was also highly comparable to the response in healthy volunteers that received a similar dose. This comparison demonstrates that the immune system of cancer patients with advanced disease remains highly responsive to TLR8 activation by VTX-2337. In summary, advanced neoplastic disease or a prior treatment history with cytotoxic agents that can negatively impact immune cell function did not appear to moderate the response to VTX-2337 based on the PK/PD relationship using predictive biomarkers. Citation Format: Greg Dietsch, Donald Northfelt, Ramesh Ramanathan, Peter Cohen, Kristi Manjarrez, Mona Newkirk, James Kyle Bryan, Robert Hershberg. Immune modulation by the TLR8 agonist VTX-2337; a comparison of the pharmacodynamic response in cancer patients and healthy volunteers. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2540. doi:10.1158/1538-7445.AM2014-2540